Enhanced Isotretinoin Risk Management Plan To Commence In Mid-2005

The program will include central registry for patients, prescribers and dispensing pharmacies, an FDA "Talk Paper" says. Celgene licenses patents covering Thalomid STEPS risk management program to isotretinoin manufacturers.

More from Archive

More from Pink Sheet